cAd3-ZEBOV (also known as the NIAID/GSK Ebola vaccine or cAd3-EBO Z) was an experimental vaccine for two ebolaviruses, Ebola virus and Sudan virus, developed by scientists at GlaxoSmithKline (GSK) and tested by National Institute of Allergy and Infectious Disease (NIAID).[1] This vaccine is derived from a chimpanzee adenovirus, Chimp Adenovirus type 3 (ChAd3), genetically engineered to express glycoproteins from the Zaire and Sudan species of ebolavirus to provoke an immune response against them. Simultaneous phase 1 trials of this vaccine commenced in September 2014, being administered to volunteers in Oxford and Bethesda.[2] During October the vaccine is being administered to a further group of volunteers in Mali. If this phase is completed successfully, the vaccine will be fast tracked for use in the Ebola virus epidemic in West Africa. In preparation for this, GSK is preparing a stockpile of 10,000 doses.[3][4]
 | |
| Vaccine description | |
|---|---|
| Target | Ebola virus |
| Vaccine type | Recombinant vector |
| Identifiers | |
| ChemSpider |
|
First British trial
editFollowing ten Americans who received the vaccine in a trial, Ruth Atkins (born 1966)[5] of Oxfordshire, a former nurse with the British National Health Service, was the first British volunteer to receive the experimental vaccine (on September 17, 2014) in a vaccine trial run by Oxford University researchers and funded by the Wellcome Trust and the UK government. This variant was only designed to protect against Ebola virus and not Sudan virus.[6]
See also
editReferences
edit- ^ Pavot V (December 2016). "Ebola virus vaccines: Where do we stand?". Clinical Immunology. 173: 44–49. doi:10.1016/j.clim.2016.10.016. PMID 27910805.
- ^ "Experimental Ebola Vaccine Processed in Maryland". Drug Discov. Dev. Associated Press. 2 October 2014.
- ^ "First British volunteer injected with trial Ebola vaccine in Oxford". Guardian. 17 September 2014. Archived from the original on 17 September 2014. Retrieved 17 September 2014.
- ^ "An Ebola vaccine was given to 10 volunteers, and there are 'no red flags' yet". Washington Post. 16 September 2014. Archived from the original on 20 February 2020. Retrieved 17 September 2014.
- ^ "First volunteer receives new Ebola vaccine in UK trial". Oxford University. 17 September 2014. Archived from the original on 2020-04-25. Retrieved 2014-10-15.
- ^ "First British volunteer injected with trial Ebola vaccine in Oxford". The Guardian. 17 September 2014. Archived from the original on 17 September 2014. Retrieved 17 September 2014.
Further reading
edit- Choi WY, Hong KJ, Hong JE, Lee WJ (January 2015). "Progress of vaccine and drug development for Ebola preparedness". Clinical and Experimental Vaccine Research. 4 (1): 11–6. doi:10.7774/cevr.2015.4.1.11. PMC 4313103. PMID 25648233.
- De Santis O, Audran R, Pothin E, Warpelin-Decrausaz L, Vallotton L, Wuerzner G, et al. (March 2016). "Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study" (PDF). The Lancet. Infectious Diseases. 16 (3): 311–20. doi:10.1016/S1473-3099(15)00486-7. PMID 26725450. Archived (PDF) from the original on 2022-03-11. Retrieved 2019-12-13.